Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer.

Maemura,M; Iino,Y; Yokoe,T; Takei,H; Horiguchi,J; Koibuchi,Y; Ikeda,F; Ohwada,S; Takeyoshi,I; Morishita,Y

doi:10.3892/or.7.6.1333

Serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen in patients with metastatic breast cancer.

Authors:
- M Maemura
- Y Iino
- T Yokoe
- H Takei
- J Horiguchi
- Y Koibuchi
- F Ikeda
- S Ohwada
- I Takeyoshi
- Y Morishita
View Affiliations

Affiliations: Second Department of Surgery, Gunma University School of Medicine, Maebashi, Gunma 371-8511, Japan. maemuram@showa.gunma-u.ac.jp
Published online on: November 1, 2000 https://doi.org/10.3892/or.7.6.1333
Pages: 1333-1341

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The serum concentration of pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) was examined in 83 patients with metastatic breast cancer. ICTP levels were significantly higher in patients with bone metastases than in those without bone metastasis. In patients with bone metastasis, significantly higher ICTP levels were observed in those with multiple lesions than in those with a solitary lesion and these levels reflected therapeutic response. Sequential monitoring of ICTP revealed that this elevation was correlated with disease progression. Combined with imaging studies, monitoring of ICTP appears to offer additional information for detection of bone metastasis and evaluation of therapeutic response to bone metastasis.